In their study, peripheral blood collected from CLL patients treated with ibrutinib as monotherapy showed down-regulation of immune checkpoint PD-L1/PD1 expression on CLL/CD8+/CD4+ T-cells respectively, which was associated with STAT3 inhibition [58]. Here, CD274 is linked to B-cell chronic lymphocytic leukemia.